Phase 3 Randomized Study Evaluating Inhaled Treprostinil Versus Placebo for Progressive Pulmonary Fibrosis Treatment
Led by United Therapeutics · Updated on 2026-07-13
698
Participants Needed
165
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying inhaled treprostinil to assess its safety and effectiveness in people with progressive pulmonary fibrosis PPF. This Phase 3, multinational, randomized, double-blind, placebo-controlled trial will compare inhaled treprostinil to a placebo over one year. The study focuses on adults diagnosed with PPF who have shown lung fibrosis progression despite standard treatments.
Participants will be randomly assigned to receive either inhaled treprostinil or a matching placebo using an ultrasonic nebulizer four times a day. The dose starts at 3 breaths per session and will be gradually increased to a target of 12 breaths per session or the highest tolerated dose. The treatment period includes six visits at weeks 4, 8, 16, 28, 40, and 52. Those completing the 52-week treatment may join an open-label extension study.
During the study, participants will undergo lung function tests like forced vital capacity FVC and lung diffusion capacity DLCO, complete questionnaires about their lung disease, and have blood tests to measure biomarkers. Researchers will monitor safety by tracking adverse events, vital signs, lab results, and electrocardiograms. The main measure is the change in lung function from the start to week 52, with additional assessments of clinical worsening, acute lung exacerbations, survival, and oxygen use.
CONDITIONS
Brief Title
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
Research Team
U
United Therapeutics Global Medical Information
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Inhaled treprostinil (a prostacyclin analogue, 6 mcg per breath), administered four times daily by nebulizer. All participants may continue standard ILD therapy (nintedanib, pirfenidone, or none, as per eligibility).
Matched inhaled placebo administered four times daily by nebulizer. All participants may continue standard ILD therapy (nintedanib, pirfenidone, or none, as per eligibility).
Role in the trial
Investigational arm; receives inhaled treprostinil plus background therapy to assess efficacy and safety for adults with progressive pulmonary fibrosis.
Randomized comparator arm; receives inhaled placebo plus background therapy to establish efficacy and safety of treprostinil by comparison.
Primary use in this trial
Being studied to determine if adding inhaled treprostinil improves lung function and clinical outcomes in people with progressive pulmonary fibrosis receiving background ILD therapy.
Serves as a control to measure the effects of background ILD therapy without treprostinil in a similar patient group.
How it is given or performed
Inhaled treprostinil is administered using a nebulizer device (6 mcg per breath) four times daily. Participants may continue background ILD therapy as per eligibility.
Placebo inhalation is administered by nebulizer four times daily, matching the investigational drug. Background ILD therapy is continued as eligible.
Evidence status (published data and guideline support)
There are no published results from this phase 3 trial in progressive pulmonary fibrosis as of the current data cutoff. Outcomes will be determined by this ongoing randomized study.
No published outcome results for this trial arm as of the current data cutoff. Efficacy of background ILD therapy with placebo in this population is under evaluation in this study.
Important limitations (evidence or trial design)
Safety and effectiveness of inhaled treprostinil in progressive pulmonary fibrosis are not yet established—results are pending. The trial excludes patients with idiopathic pulmonary fibrosis, significant emphysema, severe cardiac disease, or recent exacerbations, so findings may not apply to all individuals with fibrotic lung disease.
Findings in the placebo group may be influenced by permitted or background ILD therapy. Results are not yet available, and exclusions limit generalizability to all patients with fibrotic lung disease.
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
Participant provides voluntary informed consent to join the study.
Participant is 18 years of age or older at the time of consent.
Radiological evidence of pulmonary fibrosis covering more than 10% of the lungs on an HRCT scan within the past 12 months.
Diagnosed with progressive pulmonary fibrosis (not idiopathic pulmonary fibrosis) showing lung function decline or worsening respiratory symptoms within 24 months despite standard treatment.
Forced vital capacity (FVC) of 45% or higher predicted at screening.
Currently on nintedanib or pirfenidone treatment for at least 90 days before baseline and planning to continue, or not on these treatments and not planning to start during the study.
Use of immunosuppressive agents for at least 120 days prior to baseline and treatment is considered refractory.
Women of childbearing potential must be non-pregnant, non-lactating, and agree to abstain or use two effective contraceptive methods during the study and for 30 days after.
Men with partners of childbearing potential must agree to use condoms during treatment and for 48 hours after stopping.
Able to communicate effectively, reliable, willing, and likely to comply with study requirements.
You will not qualify if you...
Pregnant or breastfeeding individuals.
Evidence of primary obstructive airway disease or more emphysema than fibrosis on lung imaging.
Diagnosis of idiopathic pulmonary fibrosis (IPF).
Previous intolerance or poor response to prostacyclin or similar drugs causing treatment discontinuation.
Use of pulmonary arterial hypertension therapies within 60 days prior to baseline (except certain erectile dysfunction drugs under conditions).
Receiving more than 10 liters per minute of oxygen at rest at baseline.
Recent acute exacerbation of interstitial lung disease or respiratory infection within 30 days before baseline.
Uncontrolled heart disease including recent heart attack or unstable angina.
Participation in other investigational studies with medical interventions within 30 days before screening.
Recent acute pulmonary embolism within 90 days before baseline.
Any condition interfering with study assessments or participation.
Life expectancy less than 12 months due to lung disease or other illness.
Use of nerandomilast within 60 days prior to baseline.
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Treatment
Duration - 52 weeks
Participants receive inhaled treprostinil or a matching placebo via an ultrasonic nebulizer four times daily. The dose starts low and is gradually increased to a target or maximum tolerated dose. Clinic visits occur at weeks 4, 8, 16, 28, 40, and 52 to monitor progress.
6 visits at Weeks 4, 8, 16, 28, 40, and 52
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Study of 129Xe Gas Exchange MRI to Understand Lung and Heart Function in Adults
Observational Study on Risk Factors and Outcomes in Progressive Pulmonary Fibrosis Among Adults with Interstitial Lung Disease
Evaluating Inhaled Mosliciguat Versus Placebo in Adults With Pulmonary Hypertension and Interstitial Lung Disease A Randomized, Double-Blind Phase 3 Trial With Extension
Study on Body Mass Composition Using BIA and Muscle Ultrasound in Adults with IPF or Progressive Pulmonary Fibrosis Starting Anti-fibrotic Medicines
Prospective Multi-Center Registry Observing Disease Progression and Treatments in Chinese Patients with Progressive Pulmonary Fibrosis
Study of Qifangfeixian Granules for Treating Connective Tissue Disease-Associated Interstitial Lung Disease in Adults
BIO 300 with Thoracic Radiation to Reduce Lung Toxicity in Early-Stage Non-Small Cell Lung Cancer and Interstitial Lung Disease
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder Compared With Placebo in Adults With Progressive Pulmonary Fibrosis Using a Capsule-Based Dry Powder Inhaler
Phase 2 Study of Abatacept for Treating Interstitial Lung Disease in Children and Adults With Common Variable Immunodeficiency
Phase IIIa Study of Allogenic Adipose-Derived Stem Cell Therapy for Treating Connective Tissue Disease-Associated Interstitial Lung Disease in Adults
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Study Design and Rationale for the TETON-PPF Phase 3, Randomized, Controlled Clinical Trial of Inhaled Treprostinil in the Treatment of Progressive Pulmonary Fibrosis.